AGMB.US AgomAb Therapeutics NV American Depositary Shares
- Market cap
- USD 313M
- P/E
- -
- P/B
- 1.15x
- ROE
- -17.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is AGMB.US undervalued?
Graham numberThe Graham number of AgomAb Therapeutics NV American Depositary Shares cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AgomAb Therapeutics NV American Depositary Shares fundamental analysis
No fundamental analysis for AgomAb Therapeutics NV American Depositary Shares yet.
AgomAb Therapeutics NV American Depositary Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 fo…
Full company profileAgomAb Therapeutics NV American Depositary Shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AgomAb Therapeutics NV American Depositary Shares annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | - | - | - | -210K | - |
| Operating Income | -22.6M | -31.2M | -48.0M | -59.3M | -47.3M |
| EBITDA | -10.7M | -11.9M | -45.9M | -62.3M | -47.2M |
| Net Income | -8.14M | -11.4M | -46.3M | -62.5M | -46.9M |
| EPS | -0.22 | -0.31 | -1.28 | -1.28 | -0.95 |
| Balance Sheet | |||||
| Total Assets | 101M | 171M | 206M | 154M | 291M |
| Total Liabilities | 34.7M | 19.8M | 18.3M | 22.8M | 25.5M |
| Shareholders' Equity | 66.2M | 151M | 188M | 131M | 265M |
| Cash & Short-term Investments | 27.7M | 122M | 171M | 117M | 252M |
| Total Debt | - | - | - | 1.25M | 1.14M |
| Cash Flow | |||||
| Operating Cash Flow | -19.0M | -24.6M | -46.8M | -51.7M | -49.7M |
| Capital Expenditure | 0.00 | 0.00 | 675K | 4.00K | 1.45M |
| Free Cash Flow | -19.0M | -24.6M | -47.5M | -51.7M | -51.2M |
| Ratios | |||||
| ROE | -12.3% | -7.5% | -24.6% | -47.8% | -17.7% |
| ROA | -8.1% | -6.7% | -22.4% | -40.7% | -16.1% |
| Debt to Equity | - | - | - | 0.01x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
AgomAb Therapeutics NV American Depositary Shares dividends
AgomAb Therapeutics NV American Depositary Shares has not paid dividends in the last 4 fiscal years.
Who owns AgomAb Therapeutics NV American Depositary Shares
- Insiders 10.24%
- Institutions 54.74%
- Public & others 35.02%
- Shares outstanding 49.2M
- Free float 17.4M
Top funds holding AGMB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Federated Hermes Kaufmann R | 981K | 1.99% | 0.00% | Sep 2026 |
| Federated Hermes Kaufmann Small Cap A | 616K | 1.25% | 0.00% | Sep 2026 |
| Fidelity Growth Company Fund | 507K | 1.03% | 0.00% | Aug 2026 |
| abrdn Healthcare Investors | 463K | 0.94% | 0.00% | Sep 2026 |
| abrdn World Healthcare | 421K | 0.86% | +1.66% | Sep 2026 |
| abrdn Life Sciences Investors | 337K | 0.69% | +2.36% | Sep 2026 |
| Fidelity Growth Company K6 | 142K | 0.29% | 0.00% | Aug 2026 |
| Fidelity Series Growth Company | 129K | 0.26% | 0.00% | Aug 2026 |
| Biotech Growth Ord | 112K | 0.23% | 0.00% | Jul 2026 |
| ALPS Medical Breakthroughs ETF | 59.8K | 0.12% | 0.00% | Oct 2026 |
| Protea Sectoral Hlthcare Opps P USD Acc | 26.9K | 0.05% | 0.00% | Jul 2026 |
| Steward Values Enhanced International I | 23.1K | 0.05% | 0.00% | Sep 2026 |
| Federated Hermes Kaufmann II P | 17.1K | 0.03% | -18.88% | Sep 2026 |
| Protea Sectoral Biotech Opps IF USD Acc | 16.6K | 0.03% | 0.00% | Jul 2026 |
| Fidelity Nasdaq Composite Index | 9.53K | 0.02% | 0.00% | Aug 2026 |
| Fidelity Select Pharmaceuticals Port | 9.10K | 0.02% | 0.00% | Sep 2026 |
| Bellevue Diversified Healthcare U2 CHF | 1.88K | 0.00% | 0.00% | Sep 2026 |
Top institutions holding AGMB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| EQT Fund Management S.à r.l. | 5.14M | 10.44% | 0.00% | Jun 2026 |
| Nantahala Capital Management, LLC | 3.14M | 6.37% | +161.36% | Jun 2026 |
| Sanofi | 2.78M | 5.65% | 0.00% | Sep 2026 |
| Redmile Group, LLC | 2.73M | 5.55% | +1,649.71% | Jun 2026 |
| Cormorant Asset Management, LLC | 2.47M | 5.01% | 0.00% | Jun 2026 |
| TCG Crossover Management, LLC | 2.05M | 4.17% | 0.00% | Jun 2026 |
| Federated Hermes Inc | 1.62M | 3.29% | 0.00% | Jun 2026 |
| Casdin Capital, LLC | 1.55M | 3.15% | 0.00% | Jun 2026 |
| Andera Partners | 1.54M | 3.12% | 0.00% | Jun 2026 |
| FMR Inc | 1.46M | 2.96% | 0.00% | Jun 2026 |
| Aberdeen Group PLC | 847K | 1.72% | +19.65% | Jun 2026 |
| Perceptive Advisors LLC | 600K | 1.22% | 0.00% | Jun 2026 |
| Samsara BioCapital, LLC | 600K | 1.22% | 0.00% | Jun 2026 |
| Siren, L.L.C. | 411K | 0.84% | 0.00% | Jun 2026 |
| Orbimed Advisors LLC | 193K | 0.39% | 0.00% | Jun 2026 |
| Pfizer Inc | 75.0K | 0.15% | 0.00% | Jun 2026 |
| ALPS Advisors Inc | 50.0K | 0.10% | 0.00% | Jun 2026 |
| Bellevue Group AG | 49.2K | 0.10% | -1.50% | Jun 2026 |
| SEVEN GRAND MANAGERS, LLC | 47.6K | 0.10% | -76.20% | Jun 2026 |
| Sectoral Asset Management Inc | 43.5K | 0.09% | 0.00% | Jun 2026 |
AgomAb Therapeutics NV American Depositary Shares company profile
- Company name
- AgomAb Therapeutics NV American Depositary Shares
- Ticker
- AGMB.US
- Exchange
- USA Stocks
- Listed since
- Feb 6, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 62
- Fiscal year end
- December
- Address
- Posthoflei 1/6, Antwerp, Belgium, 2600
- Phone
- 32 3 318 91 70
- Website
- agomab.com
About AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
AgomAb Therapeutics NV American Depositary Shares management
8- Dr. Tim Knotnerus MSc, Ph.D.CEO & Executive Director · born 1983
- Mr. Paolo Michieli Ph.D.Founder, Senior Advisor & Member of Scientific Advisory Board
- Mr. Pierre Kemula B.Sc.Chief Financial Officer · born 1974
- Sofie Van GijselVice President of Investor Relations
- Ms. Ellen LefeverGeneral Counsel · born 1985
- Dr. Philippe Wiesel M.D.Chief Medical Officer · born 1967
- Dr. Paul Van Der Horst Ph.D.Chief Business Officer · born 1988
- Dr. Andrea Sáez Borderías Ph.D.Chief Development Officer · born 1982